Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

by · The Cerbat Gem

Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totaling 265,115 shares, a growth of 411.7% from the August 15th total of 51,809 shares. Based on an average daily trading volume, of 1,250,016 shares, the days-to-cover ratio is presently 0.2 days. Approximately 6.3% of the shares of the stock are sold short.

Insider Buying and Selling at Bluejay Diagnostics

In related news, major shareholder Financial Lp Hrt bought 64,047 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was purchased at an average price of $1.51 per share, for a total transaction of $96,710.97. Following the completion of the transaction, the insider owned 126,993 shares in the company, valued at $191,759.43. The trade was a 101.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent filing with the SEC. Institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Stock Down 11.2%

Bluejay Diagnostics stock traded down $0.11 during mid-day trading on Friday, reaching $0.90. 319,394 shares of the company’s stock traded hands, compared to its average volume of 3,133,148. Bluejay Diagnostics has a 12-month low of $0.82 and a 12-month high of $16.68. The stock has a 50 day moving average of $1.06 and a two-hundred day moving average of $1.92. The company has a market cap of $4.01 million, a price-to-earnings ratio of -0.13 and a beta of 0.91.

Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, topping analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wall Street Zen raised shares of Bluejay Diagnostics from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

View Our Latest Stock Analysis on Bluejay Diagnostics

Bluejay Diagnostics Company Profile

(Get Free Report)

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.

Further Reading